Medical devices, healthcare technology and the business of care
PMA approval · P010033

QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE

Qiagen · Decision date Nov 28, 2001

FDA DECISIONP010033

What did the FDA approve?

FDA records P010033 as an original PMA application. The recorded decision is approval, dated Nov 28, 2001.

FDA approval order statement

APPROVAL FOR THE CELLESTIS QUANTIFERON-TB. THE DEVICE IS INDICATED FOR USE AS AN AID IN THE DETECTION OF INFECTION WITH MYCOBACTERIUM TUBERCULOSIS.
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
Nov 28, 2001

FDA source record

Regulatory record facts

Identifier
P010033
Regulatory pathway
Premarket approval application
Applicant
Qiagen
Product code
NCD
Decision code
APPR
Decision date
Nov 28, 2001
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.

Applicant
Qiagen
Product code
NCD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P010033 received

    Application receipt date recorded by FDA.

  2. P010033 · FDA decision

    APPR

  3. P010033/S053 · Related supplement

    QuantiFERON-TB Gold Plus Test

Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010033

Product / regulatory recordCompanyPathwayDecision dateSource
QiagenPMA supplementOct 14, 2026FDA

Explore the linked device profile

Other records with product code NCD

Product / regulatory recordCompanyPathwayDecision dateSource
DiaSorin, Inc.PMA supplementSep 24, 2026FDA
DiaSorin, Inc.PMA approvalNov 26, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Qiagen

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
19300 Germantown Rd., Germantown, MD, 20874

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records